Difference between revisions of "LINC00857"

From LncRNAWiki
Jump to: navigation, search
(→‎Function)
 
(4 intermediate revisions by the same user not shown)
Line 17: Line 17:
  
 
===Characteristics ===
 
===Characteristics ===
−
[[File:Functional domains of 7SK RNA..png|right|thumb|Functional domains of 7SK RNA([https://www.ncbi.nlm.nih.gov/pubmed/19246988 (Diribarne 2009)])]]
+
[[File:LINC00857 expression in MIBC.jpg|right|thumb|LINC00857 expression in MIBC]]
  
 
Please input characteristics information here.
 
Please input characteristics information here.
  
 
===Expression===
 
===Expression===
−
Was found to be upregulated in tumors from patients that did not respond to platinum‐based chemotherapy<ref name="ref1" />.
+
Was found to be upregulated in tumors from bladder cancer patients that did not respond to platinum‐based chemotherapy<ref name="ref1" />.
 +
 
 +
Was identified as one of the most upregulated lncRNAs in lung cancer<ref name="ref1" />.
 +
 
 +
High LINC00857 expression was associated with shorter overall survival of patients with lung cancer<ref name="ref1" />.
  
 
===Regulation===
 
===Regulation===
−
In the 7SK ribonucleoprotein, Larp7 binds directly to 3′ terminus of 7SK RNA ([https://www.ncbi.nlm.nih.gov/pubmed/18281698 (Krueger 2008)]) ([https://www.ncbi.nlm.nih.gov/pubmed/18483487 (Markert 2008)]), and prevents degradation of 7SK in vivo ([https://www.ncbi.nlm.nih.gov/pubmed/18281698 (Krueger 2008)]).
+
Please input regulation information here.
  
 
===Function===
 
===Function===
−
[[File:Model of hLarp7 recognition of the 7SK.png|right|thumb|Model of hLarp7 recognition of the 7SK 3′end and mechanism of assembly of core 7SK RNP([https://www.ncbi.nlm.nih.gov/pubmed/29946027 (Eichhorn 2018)])]]
+
[[File:Effect of LINC00857 on cisplatin sensitivity.jpg|right|thumb|Effect of LINC00857 on cisplatin sensitivity]]
  
 
LINC00857 plays an important role in the regulation of response to platinum‐based chemotherapy. LINC00857 potentially could serve as a novel prognostic and predictive biomarker and might be a therapeutic target to overcome cisplatin resistance in patients with MIBC<ref name="ref1" />.
 
LINC00857 plays an important role in the regulation of response to platinum‐based chemotherapy. LINC00857 potentially could serve as a novel prognostic and predictive biomarker and might be a therapeutic target to overcome cisplatin resistance in patients with MIBC<ref name="ref1" />.
 +
 +
It is likely that LINC00857 regulates the expression of LMAN1 and PPP2R5E and other target genes by affecting mRNA stability or promoting its translation leading to resistance to platinum‐induced apoptosis<ref name="ref1" />.
  
 
===Disease===
 
===Disease===
−
colon adenocarcinoma <ref name="ref1" />
+
* bladder cancer<ref name="ref1" />
 +
* lung cancer
  
 
===Evolution===
 
===Evolution===

Latest revision as of 01:27, 12 August 2019

Annotated Information

Name

Approved symbol: LINC00857

Approved name: long intergenic non-protein coding RNA 857

HGNC ID: HGNC:45114

RefSeq ID: NR_038464

Ensembl ID: ENSG00000237523

LncBook ID: HSALNT0165271

Chromosome

10q22.3

Characteristics

LINC00857 expression in MIBC

Please input characteristics information here.

Expression

Was found to be upregulated in tumors from bladder cancer patients that did not respond to platinum‐based chemotherapy[1].

Was identified as one of the most upregulated lncRNAs in lung cancer[1].

High LINC00857 expression was associated with shorter overall survival of patients with lung cancer[1].

Regulation

Please input regulation information here.

Function

Effect of LINC00857 on cisplatin sensitivity

LINC00857 plays an important role in the regulation of response to platinum‐based chemotherapy. LINC00857 potentially could serve as a novel prognostic and predictive biomarker and might be a therapeutic target to overcome cisplatin resistance in patients with MIBC[1].

It is likely that LINC00857 regulates the expression of LMAN1 and PPP2R5E and other target genes by affecting mRNA stability or promoting its translation leading to resistance to platinum‐induced apoptosis[1].

Disease

  • bladder cancer[1]
  • lung cancer

Evolution

Please input evolution information here.

Labs working on this lncRNA

  • Department of Urology, Radboud Institute for Molecular Life Sciences, Radboud university medical center, Nijmegen, The Netherlands.
  • Department for Health Evidence, Radboud Institute for Health Sciences, Radboud university medical center, Nijmegen, The Netherlands.

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 1.5 Dudek AM, van Kampen JGM, Witjes JA, et al. LINC00857 expression predicts and mediates the response to platinum-based chemotherapy in muscle-invasive bladder cancer[J]. Cancer Med, 2018.

Sequence

>gi|336285291|ref|NR_038464.1| Homo sapiens long intergenic non-protein coding RNA 857 (LINC00857), long non-coding RNA

000001 GACCGCGAAG GCCAGCTTCT TCGAAAGGCC CATTTTTCTC CGTGGCTGAG CGAATGCTCC TAGAATACCA CGTTTATAAT 000080
000081 AAATCATGTA GGGTGGAATT CCTGCTGGAT GTATACACCT TTCTGCATCA GAGCTCTTCA AACCCAGAAT GGTGAATAGC 000160
000161 TACCCCTGGG CTTACCCTTT TATAATTTTC AACAAACCTG CGTTTAGCCC CGGCTAGGTG CCAGCAAGTT GCTAGGGACT 000240
000241 GAGGAGGCTC TGCAGAGGAC CCGAGCTGAG GCCCTAATCC TCAAGGCCAA TGGCAGGGGT CACCGCCCAG GCACCCCCAG 000320
000321 AGAACGCGGT GTGAAGGAAA AGACACCAAA CTCGGTGTTC AAATGTGTGG GATCTATTCT AGTTCTGATT CTGACACTTG 000400
000401 CAAGTCATGC ATCCTCCGAG CCTCGGCTTT CTCACCTATA AAATCTTCAA CGTGACCTAT AAAAATCCAT AAAATCACCC 000480
000481 CTGCTTCATT GTTTCCCAGG GCTCATAGAA ACATCATACA AGGTGGAGAA GAGTACCCAA GAAGGACAAG CTTGGAATGG 000560
000561 GGCCCCCTCC CCAGGCTGGA GATCAGACAT TGTTGGAGAA GGTATCATTG CAGCCCCCTA CATAGCAGAG AGATTTGCTG 000640
000641 AGTTGCATAG TCTAGAGCTG GTTGCAATTA TTGGACAAGC AGGAAACAAA CCTCCACAGC CCATGCGAGC CACACTGCTG 000720
000721 GGTTGAGTGT ATGAGCATGT AGAATGATTG GGTCTCCAGT GCGGACAGAA GGCATGGATC GCGTGGTGCC TGTGTTGGGA 000800
000801 GGATACTAAG AGGGCGATCA CCATGCCAGG ACAAGACTAG TTGCCTGGGA TCTTCTGGGC ACGTGACTGG AGCAGAGTAC 000880
000881 CACTGGATCT CCTCACACCA GCCAGACCCA GGAAGAGAAG CTCCTTTCAC CTGCACTGTT CTCTCAGCAC CCTCCACGGA 000960
000961 GAAAGCTTCA TGTTATGCTT AGTGTACAGG AGAAATGCTC ATGGGAATCC TGTCCATTAT CACAGAGCAG GTATTAGTGG 001040
001041 GTGAATATGG AGCTGAGAAG TAATAAGTTG TAACTGGCAT AGATATCATG GGGATATTTG AAGAACGCTG TGAACACATA 001120
001121 TGCATGGGTC CATGTATTCA TGAGTGTGCA CATATGTGTA ATTATTCATA CAATTCATGG TGGATACTAC TTCGAGGGTG 001200
001201 TTCACAGACC CCAGGCAGAG AGCGCCTGGA GGGAAAATTA TCCAAGGCAG GCCCATTCAT AGTTCCAGGA CAGCCAGAAG 001280
001281 AAAGCCTCCG TTAAGCACCA GAAGTCTCCG GGGCAGGTGG GGCCAGGCAG CATGAAAGAA TTGGCCGCAA GAGTTCCAAA 001360
001361 CCCTGTCCCA ATTATGGAGG GTGACTTTTC TTTGTCCTCC TTCTCCATTC CCTTCCATAT TGCTCATGCA TCCAAAGGGA 001440
001441 GACCTGAAGA CTCTCTAGCA GGGCAAGGCC ATTTTCTTTT GGCATTTTTC TCTCCCCAGA GTCTAGCTGA TTATCAGCTT 001520
001521 AGACACACAG CAGGCTATGT GCTGTGAACA ACAGGCATCC TGGGTTATTT TACAAACTCA TGGATAGTCA TTTTGAAACC 001600
001601 ACCTTTGCAA AATTGTGACT GAAACAGTGA AAGAGAGCTA ACTTAACCAG CTCCATCTTG TTTCTAACCT CCAAGCTGTC 001680
001681 TTTGTTCATT CCTGGGCGTA GGCTGAACTA ACTTTGGGAG AAACTTAGTT TGTAGTTATA GTTTAAACAA AGACTGTGAC 001760
001761 AGCCCTTTCC CAATGCAGAC CTCCTTCTTG TCTGGGGACT AGACTAACAT TAGCCACAGG ATTAGA